These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 11999139)

  • 1. Usage of triptans among migraine patients: an audit in nine GP practices.
    Williams D; Cahill T; Dowson A; Fearon H; Lipscombe S; O'Sullivan E; Rees T; Strang C; Valori A; Watson D
    Curr Med Res Opin; 2002; 18(1):1-9. PubMed ID: 11999139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
    Perearnau P; Vuillemet F; Schick J; Weill G
    Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey--phase IV.
    MacGregor EA; Brandes J; Gendolla A; Giammarco R
    Curr Med Res Opin; 2004 Nov; 20(11):1777-83. PubMed ID: 15537478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Triptan Usage in Korea: A Population-Based Cohort Study.
    Ha WS; Jeong J; Song S; Yum J; Chu MK
    J Korean Med Sci; 2024 Aug; 39(31):e222. PubMed ID: 39137809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying the factors underlying discontinuation of triptans.
    Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.
    Tepper S; Allen C; Sanders D; Greene A; Boccuzzi S
    Headache; 2003 Jan; 43(1):44-8. PubMed ID: 12864757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
    Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
    Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The triptan formulations : how to match patients and products.
    Rapoport AM; Tepper SJ; Bigal ME; Sheftell FD
    CNS Drugs; 2003; 17(6):431-47. PubMed ID: 12697002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptans for Acute Migraine Headache: Current Experience With Triptan Use and Prescription Habits in a Tertiary Care Headache Outpatient Clinic: An Observational Study.
    Fischer M; Frank F; Wille G; Klien S; Lackner P; Broessner G
    Headache; 2016 Jun; 56(6):952-60. PubMed ID: 27091593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic comparison of frovatriptan versus other oral triptans in the treatment of acute migraine in the real-world setting.
    Guidotti M; Ravasio R
    Clin Drug Investig; 2009; 29(11):693-702. PubMed ID: 19813772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
    Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
    Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptan education and improving knowledge for optimal migraine treatment: an observational study.
    Baron EP; Markowitz SY; Lettich A; Hastriter E; Lovell B; Kalidas K; Dodick DW; Schwedt TJ;
    Headache; 2014 Apr; 54(4):686-97. PubMed ID: 24520930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of adherence to triptans: factors of sustained vs lapsed users.
    Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
    Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Zolmitriptan as fast-melt tablet in the acute treatment of patients with migraine attacks: the ZORO study].
    Stöckli HR; Sword A
    Praxis (Bern 1994); 2003 Feb; 92(9):379-89. PubMed ID: 12674591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
    Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
    Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
    Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
    J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac risk factors and the use of triptans: a survey study.
    Young WB; Mannix L; Adelman JU; Shechter AL
    Headache; 2000; 40(7):587-91. PubMed ID: 10940098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.